W
ith an increasingly aging population, aortic stenosis (AS) has become the most frequent valvular heart disease in North America and Europe. It is a progressive condition characterized by a long latent asymptomatic period, followed by a shorter symptomatic stage associated with increased morbidity and higher mortality. Nevertheless, despite these well-established criteria on the appropriateness of AVR intervention, the management of asymptomatic patients with preserved LV systolic function continues to be controversial (2) . Registry data indicate that 15% of patients undergoing AVR are asymptomatic at the time of surgery (3). Novel markers to improve risk stratification would be valuable in identifying asymptomatic patients who would benefit from AVR.
Over the past 2 decades, cardiovascular magnetic resonance (CMR) has been increasingly adopted in clinical practice in the work-up of ischemic and nonischemic cardiomyopathies (4, 5) . CMR is used as an advanced diagnostic tool to accurately assess biventricular anatomy and function, but its unique application is in vivo myocardial tissue characterization. Indeed, it has been widely demonstrated that the late gadolinium enhancement (LGE) technique allows the accurate assessment of myocardial replacement fibrosis in both ischemic and nonischemic cardiomyopathies. Importantly, replacement fibrosis by LGE has been found to represent a ubiquitous marker of adverse prognosis in ischemic heart disease, nonischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, cardiac sarcoidosis, cardiac amyloidosis, and biopsy-proven myocarditis (6) (7) (8) (9) (10) (11) . This suggests that the time has come for a paradigm shift from "bright is dead" to "bright is bad." Myocardial enhancement is not only a marker of myocardial scarring/necrosis, as seen in ischemic heart disease, as it represents a broader spectrum of myocardial damage in a variety of cardiomyopathies.
In the context of severe AS, the degree of myocardial fibrosis plays an important role in the transition from well-compensated hypertrophy to overt heart failure and risk of sudden cardiac death (12) , suggesting that LGE is a marker of more advanced disease (13) .
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